ANI debuts generic Fleqsuvy

ANI Pharmaceuticals is releasing baclofen oral suspension, which is a generic version of Azurity's Fleqsuvy.

Generic Fleqsuvy is a treatment for spasticity from multiple sclerosis or spinal cord injuries and other spinal cord diseases.

[Read more: ANI obtains FDA OK for generic Divigel]

"The launch of baclofen oral suspension represents another entry for ANI into a rapidly growing limited competition market. We are proud of our ability to recognize the market need and provide our customers with the best suited packing configurations to match their requirements in a timely manner,” said Nikhil Lalwani, president and CEO of ANI.

Baclofen Oral Suspension had a market value of approximately $39 million, per IQVIA data.

[Read more: ANI Pharmaceuticals receives ​​​​​​​FDA nod for generic Furadantin]